T 89

Drug Profile

T 89

Alternative Names: Cardiotonic Pills; Compound Danshen Dripping Pills; Danshen Plus; Dantonic Capsule; Salvtonic; T89; Tasly Danshen Plus Capsule

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tianjin Tasly Pharmaceutical
  • Developer Tasly Pharmaceutical Group; Tasly Pharmaceuticals, Inc.
  • Class Herbal medicines; Ischaemic heart disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Angina pectoris
  • Phase III Diabetic retinopathy
  • Phase I/II Respiration disorders

Most Recent Events

  • 13 Jul 2017 Tasly Pharmaceuticals completes a phase I/II trial in Respiration disorders (In volunteers) in China (NCT03270787)
  • 01 Dec 2016 Tasly Pharmaceuticals completes a phase III trial in Angina pectoris in USA, Belarus, Georgia, Mexico, Ukraine, Russia and Canada (PO) (NCT01659580)
  • 01 May 2013 Phase-III clinical trials in Diabetic retinopathy in China (PO) (NCT02388984)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top